Nialamide, an MAO inhibitor, increases urinary excretion of endogenously produced bufotenin in man.
Nialamide, an MAO inhibitor, was given per os (PO) to a normal man who volunteered in two separate trials (total intake 300 mg and 1000 mg, respectively), and his bufotenin excretion was followed by consecutive urine samples. In both experiments the excretion rose well above the values measured from the same test subject when not taking nialamide (median 0.089 nmol/mmol creatinine, range 0.002-1.78). At its highest, the excretion was 16.5 nmol/mmol creatinine, and the maximum urinary output was 495 nmoles (56 micrograms) in 24 hr. The levels of bufotenin in plasma required for the excretion of the latter amounts are not far from those that produce psychic symptoms in man.
Kärkkäinen
J
J
Department of Medical Chemistry, University of Helsinki, Finland.
Räisänen
M
M
D000284:Administration, Oral; D000328:Adult; D002027:Bufotenin / Q000652:urine*; D006801:Humans; D008297:Male; D009526:Nialamide / Q000494:pharmacology*; D012016:Reference Values
D002027:Bufotenin; D009526:Nialamide